The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ACADEMIA
ACADEMIA
- Low-Dose Aspirin Might Cut Dementia Risks in Diabetes Women: Researchers
December 5, 2019
- National Neurology Center Starts Investigator-Led Trial for DMD Drug Targeting Exon 44
November 8, 2019
- Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
October 28, 2019
- Nephrology Society Poised to Compile Drug Development Guidelines for Early-Stage Kidney Disease
October 18, 2019
- Cancer Institute Hospital Opens Development Center to Resolve Challenges of Immunotherapy with Pharma Companies
October 18, 2019
- Research Group at Tokyo Medical and Dental Univ. Succeeds in Producing Multi-Organ Structure from iPS Cells
September 27, 2019
- Drug Makers Evaluating MSLs Using Both Qualitative, Quantitative Criteria: JAPhMed Survey
September 25, 2019
- High Response Rate in Brain Metastasis Patients Earned High Marks for Rozlytrek’s Sakigake Status: Oncologist
September 6, 2019
- Anticoagulant Monotherapy Does Not Increase CV Events in Coronary Artery Disease Patients with AF: Cardiovascular Center
September 6, 2019
- 4 Scientific Societies Submit Proposal to Health Minister to Ensure Stable Antibiotic Supplies
September 4, 2019
- Investigator-Led Clinical Trial to Get Underway for Next-Gen Oncolytic Virus
August 28, 2019
- 80% of Diabetes Patients on Antihypertensives Use ACE Inhibitors/ARBs: MHLW Study
August 19, 2019
- 5-Year Cancer Survival Rates in Japan Stand at 66.1%: NCC
August 9, 2019
- NCC Hospital Crafting Scheme to Offer Off-Label Meds after Genomic Profiling
July 23, 2019
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- Japanese Data More Positive for Keytruda’s Frontline Use in Gastric Cancer
July 22, 2019
- Keytruda Shows Promise in Japanese HCC Patients despite Global Miss
July 22, 2019
- Keytruda Slashes Death Risk by 78% in Japanese Head and Neck Cancer Patients
July 19, 2019
- New Pancreatic Cancer Guidelines Recommend FOLFIRINOX as 1st-Line Therapy
July 19, 2019
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…